A Phase 1/2, Multicenter, Open-label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)
Latest Information Update: 07 Feb 2018
Price :
$35 *
At a glance
- Drugs Elosulfase alfa (Primary)
- Indications Mucopolysaccharidosis IV
- Focus Adverse reactions
- Sponsors BioMarin Pharmaceutical
- 05 Feb 2018 According to a BioMarin Pharmaceutical media release, data will be presented at the 14th Annual WORLDSymposiumTM 2018.
- 25 Feb 2014 New trial record